Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Study for patients with Uveal Melanoma using study drug crizotinib
Sponsor: Pfizer
Enrolling: Male and Female Patients
Study Length: 48 Weeks
IRB Number: AAAO8010
U.S. Govt. ID: NCT02223819
Contact: Richard Carvajal: 646-317-6041 /
Additional Study Information: The purpose of the treatment part of the study is to find out what effects drug crizotinib has, good and/or bad on people with "high risk" uveal melanoma after surgery or radiation for the eye. It is thought that giving crizotinib to patients with "high risk" uveal melanoma can lower the chance the cancer will come back. Uveal melanoma is a type of cancer that starts in the back of the eye that is treated with surgery or radiation. After this treatment, about half of all uveal melanomas come back in another part of body, called metastasis. Crizotinib is an anticancer pill that is FDA approved for patients with some kinds of lung cancer. It blocks the spread of uveal melanoma in the laboratory. Subjects who enroll on the study will be asked to take crizotinib at a dose of 250 mg, one pill, twice every day for 48 weeks.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with uveal melanoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Richard Carvajal